NASDAQ · KZIA
Kazia Therapeutics Ltd ADR
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
Loading market information…
NASDAQ · ACON · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aclarion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Aclarion, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$1.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aclarion, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 15, 2025 |
| -$9.32+99.36% vs estimate |
| $18.99K-5.05% vs estimate |
| Q4 2024 | Mar 27, 2025 | -$1,551.93-3,003.86% vs estimate | $10.23K |
|---|
| Q3 2024 | Nov 14, 2024 | -$1,351.35+16.67% vs estimate | $14.41K-3.95% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
$0.51+$0.02 (+3.88%)
Bullfrog AI Holdings, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 74.18% below the high.
$0.44-$0.01 (-3.16%)
Ensysce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.36% below the high.
$0.37-$0.01 (-1.55%)
Soligenix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
$2.34-$0.30 (-11.36%)
Titan Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.55% below the high.
$5.85-$0.21 (-3.47%)
Clearmind Medicine Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.81% below the high.
$1.69+$0.04 (+2.42%)
Can-Fite BioPharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 86.37% below the high.
$1.25-$0.09 (-6.72%)
Silo Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.02% below the high.
